Pharsight

Viiv Hlthcare patents expiration

1. Apretude patents expiration

APRETUDE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(1 year, 10 months from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(1 year, 10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

APRETUDE family patents

Family Patents

2. Cabenuva Kit patents expiration

CABENUVA KIT's oppositions filed in EPO
CABENUVA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6838464 VIIV HLTHCARE 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
Feb, 2021

(3 years ago)

US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 2 months ago)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(10 months from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(1 year, 10 months from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(1 year, 10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(3 years from now)

US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026
New Patient Population(NPP) Mar 29, 2025
New Dosing Schedule(D-184) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Combivir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5859021

(Pediatric)

VIIV HLTHCARE Antiviral combinations
Nov, 2012

(11 years ago)

US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

US5905082

(Pediatric)

VIIV HLTHCARE Crystalline oxathiolane derivatives
Nov, 2016

(7 years ago)

Drugs and Companies using LAMIVUDINE; ZIDOVUDINE ingredient

Market Authorisation Date: 26 September, 1997

Treatment: Treatment of hiv

Dosage: TABLET;ORAL

More Information on Dosage

COMBIVIR family patents

Family Patents

4. Dovato patents expiration

DOVATO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(5 years from now)

US11234985 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 08, 2022
New Indication(I-839) Aug 06, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents

5. Epivir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

US5905082

(Pediatric)

VIIV HLTHCARE Crystalline oxathiolane derivatives
Nov, 2016

(7 years ago)

US6004968 VIIV HLTHCARE Pharmaceutical compositions containing lamivudine
Mar, 2018

(6 years ago)

US6004968

(Pediatric)

VIIV HLTHCARE Pharmaceutical compositions containing lamivudine
Sep, 2018

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-147) Mar 23, 2018

Drugs and Companies using LAMIVUDINE ingredient

Market Authorisation Date: 17 November, 1995

Treatment: NA

Dosage: SOLUTION;ORAL; TABLET;ORAL

More Information on Dosage

EPIVIR family patents

Family Patents

6. Epzicom patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6417191 VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Mar, 2016

(8 years ago)

US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

US6417191

(Pediatric)

VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Sep, 2016

(7 years ago)

US5905082

(Pediatric)

VIIV HLTHCARE Crystalline oxathiolane derivatives
Nov, 2016

(7 years ago)

US6294540 VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
May, 2018

(6 years ago)

US6294540

(Pediatric)

VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Nov, 2018

(5 years ago)

Drugs and Companies using ABACAVIR SULFATE; LAMIVUDINE ingredient

Market Authorisation Date: 02 August, 2004

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of EPZICOM before it's drug patent expiration?
More Information on Dosage

EPZICOM family patents

Family Patents

7. Juluca patents expiration

JULUCA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7067522 VIIV HLTHCARE 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
Dec, 2019

(4 years ago)

US6838464 VIIV HLTHCARE 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
Feb, 2021

(3 years ago)

US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 2 months ago)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(10 months from now)

US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

US10426780 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 VIIV HLTHCARE Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(1 year, 10 months ago)

US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Combination(NC) Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage

JULUCA family patents

Family Patents

8. Lexiva patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6436989 VIIV HLTHCARE Prodrugs of aspartyl protease inhibitors
Dec, 2017

(6 years ago)

US6436989

(Pediatric)

VIIV HLTHCARE Prodrugs of aspartyl protease inhibitors
Jun, 2018

(5 years ago)

US6514953 VIIV HLTHCARE Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
Jul, 2019

(4 years ago)

US6514953

(Pediatric)

VIIV HLTHCARE Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
Jan, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Oct 27, 2015
New Patient Population(NPP) Apr 27, 2015

Drugs and Companies using FOSAMPRENAVIR CALCIUM ingredient

Market Authorisation Date: 20 October, 2003

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL; SUSPENSION;ORAL

How can I launch a generic of LEXIVA before it's drug patent expiration?
More Information on Dosage

LEXIVA family patents

Family Patents

9. Rescriptor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5563142 VIIV HLTHCARE Diaromatic substituted compounds as anti-HIV-1 agents
Oct, 2013

(10 years ago)

US6177101 VIIV HLTHCARE Delavirdine high strength tablet formulation
Jun, 2019

(5 years ago)

Drugs and Companies using DELAVIRDINE MESYLATE ingredient

Market Authorisation Date: 04 April, 1997

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

RESCRIPTOR family patents

Family Patents

10. Rukobia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461333 VIIV HLTHCARE Salts of prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(8 months from now)

US7745625 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Nov, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168615 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Jul, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 02, 2025

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

NCE-1 date: 02 July, 2024

Market Authorisation Date: 02 July, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

RUKOBIA family patents

Family Patents

11. Selzentry patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6586430 VIIV HLTHCARE CCR5 modulators
Dec, 2019

(4 years ago)

US7576097 VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2021

(3 years ago)

US6667314 VIIV HLTHCARE Tropane derivatives useful in therapy
Aug, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6586430 VIIV HLTHCARE CCR5 modulators
Dec, 2019

(4 years ago)

US7576097 VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2021

(3 years ago)

US6667314 VIIV HLTHCARE Tropane derivatives useful in therapy
Aug, 2021

(2 years ago)

US7576097

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2021

(2 years ago)

US6667314

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Feb, 2022

(2 years ago)

US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2022

(1 year, 6 months ago)

US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2023

(1 year, 20 days ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 28, 2013
New Strength(NS) Nov 04, 2019
New Chemical Entity Exclusivity(NCE) Aug 06, 2012

Drugs and Companies using MARAVIROC ingredient

NCE-1 date: 07 August, 2011

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL; SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's drug patent expiration?
More Information on Dosage

SELZENTRY family patents

Family Patents

12. Tivicay patents expiration

TIVICAY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-758) Nov 21, 2020
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
M(M-166) Jul 30, 2018

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 09 June, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage

TIVICAY family patents

Family Patents

13. Tivicay Pd patents expiration

TIVICAY PD's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(5 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Market Authorisation Date: 12 June, 2020

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TIVICAY PD before it's drug patent expiration?
More Information on Dosage

TIVICAY PD family patents

Family Patents

14. Triumeq patents expiration

TRIUMEQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

US6294540 VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
May, 2018

(6 years ago)

US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6417191 VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Mar, 2016

(8 years ago)

US6417191

(Pediatric)

VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Sep, 2016

(7 years ago)

US5905082

(Pediatric)

VIIV HLTHCARE Crystalline oxathiolane derivatives
Nov, 2016

(7 years ago)

US6294540

(Pediatric)

VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Nov, 2018

(5 years ago)

US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-294) Jun 15, 2026
Pediatric Exclusivity(PED) Dec 15, 2026
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Dosing Schedule(D-147) Mar 23, 2018

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

NCE-1 date: 15 December, 2025

Market Authorisation Date: 22 August, 2014

Treatment: Treatment of human immunodeficiency virus (hiv) infection.

Dosage: TABLET;ORAL

How can I launch a generic of TRIUMEQ before it's drug patent expiration?
More Information on Dosage

TRIUMEQ family patents

Family Patents

15. Triumeq Pd patents expiration

TRIUMEQ PD's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 15, 2026
Pediatric Exclusivity(PED) Dec 15, 2026

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 30 March, 2022

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TRIUMEQ PD before it's drug patent expiration?
More Information on Dosage

TRIUMEQ PD family patents

Family Patents

16. Trizivir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6417191 VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Mar, 2016

(8 years ago)

US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

US6417191

(Pediatric)

VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Sep, 2016

(7 years ago)

US5905082

(Pediatric)

VIIV HLTHCARE Crystalline oxathiolane derivatives
Nov, 2016

(7 years ago)

US6294540 VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
May, 2018

(6 years ago)

US6294540

(Pediatric)

VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Nov, 2018

(5 years ago)

Drugs and Companies using ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE ingredient

Market Authorisation Date: 14 November, 2000

Treatment: Treatment of hiv; Method of treatment of a patient infected with hiv

Dosage: TABLET;ORAL

How can I launch a generic of TRIZIVIR before it's drug patent expiration?
More Information on Dosage

TRIZIVIR family patents

Family Patents

17. Vocabria patents expiration

VOCABRIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(1 year, 10 months from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(1 year, 10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026
New Patient Population(NPP) Mar 29, 2025
M(M-273) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR SODIUM ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: TABLET;ORAL

More Information on Dosage

VOCABRIA family patents

Family Patents

18. Ziagen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6294540 VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
May, 2018

(6 years ago)

US6294540

(Pediatric)

VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Nov, 2018

(5 years ago)

US6641843 VIIV HLTHCARE Pharmaceutical compositions
Feb, 2019

(5 years ago)

US6641843

(Pediatric)

VIIV HLTHCARE Pharmaceutical compositions
Aug, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-147) Mar 23, 2018

Drugs and Companies using ABACAVIR SULFATE ingredient

Market Authorisation Date: 17 December, 1998

Treatment: Method of treatment of a patient infected with hiv

Dosage: SOLUTION;ORAL; TABLET;ORAL

How can I launch a generic of ZIAGEN before it's drug patent expiration?
More Information on Dosage

ZIAGEN family patents

Family Patents